A Multidisciplinary Approach to CAR T-cell Therapy for Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Episode 6
Multidisciplinary Clinical Perspectives: Factors That Influence CAR T-Cell Sequencing in B-ALL
Experts discuss the chimeric antigen receptor (CAR) T-cell treatment paradigm at Moffitt Cancer Center, exploring how treatment sequencing differs for Philadelphia chromosome–positive vs –negative acute lymphoblastic leukemia (ALL), varying risk factors, extramedullary disease, disease bulk, and bone marrow blast percentage, as well as how prior therapies such as blinatumomab and inotuzumab affect treatment selection for adult patients with CD19-positive or CD22-positive relapsed or refractory disease and the influence of clinical trial data on patient care.
Video content above is prompted by the following:
With respect to the CAR T-cell treatment paradigm at Moffitt Cancer Center, does the treatment sequencing differ for Philadelphia chromosome–positive vs –negative ALL; lower vs higher risk factors and/or extramedullary disease; and bulk of disease or percentage of bone marrow blasts?
- How does treatment in earlier lines of therapy (eg, blinatumomab, inotuzumab) affect treatment selection for adult patients with CD19-positive or CD22-positive relapsed or refractory disease?
- What prior therapies most significantly affect CAR T-cell outcomes?How do clinical trials data factor into the care of patients with B-cell ALL?
